Insera Therapeutics, LLC.(Insera Therapeutics) has received a Phase I small business innovation research (SBIR) grant from the National Science Foundation (NSF). Insera will use the $150,000 grant to develop the clot-specific catheter-based platform for treatment of ischemic strokes.
“Winning this grant will enable us to leap-frog existing approaches to create a versatile platform for use during stroke thrombolysis and mechanical thrombectomy, as well as during angioplasty and stenting,” said Vikram Janardhan, CEO of Insera Therapeutics. “Insera’s disruptive technology will reshape catheter-based treatments for a wide range of vascular diseases and disorders, and most importantly, help drive down healthcare costs for the consumer.”
“This grant award is a testament to the unique and innovative elements of Insera’s technology platform especially in light of the fact that this was their very first time proposing to the National Science Foundation,” said Peter Bernardoni, Managing Director of Wavepoint Ventures and a member of Insera’s advisory board.
“Insera’s plan to supplant federal funding with external investment from the venture capital community is a pragmatic example of a public-private partnership to help expedite the commercialization of this important life-saving medical device platform,” said J.D. Stack, CEO of The Sacramento Area Regional Technology Alliance (SARTA), a technology-focused not-for-profit corporation established to support Sacramento-based startups like Insera.
Insera Therapeutics is a medical devices company developing innovative products for treatment of various neurovascular diseases.